We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





HORIBA Unveils New Compact Hematology Analyzers with Combined ESR and CBC/Diff

By LabMedica International staff writers
Posted on 31 Jul 2024
Print article
mage: The new compact hematology analyzers with combined ESR and CBC/Diff presented at ADLM 2024 (Photo courtesy of HORIBA)
mage: The new compact hematology analyzers with combined ESR and CBC/Diff presented at ADLM 2024 (Photo courtesy of HORIBA)

HORIBA (Kyoto, Japan) is attending this year's ADLM where the company is showcasing its newly launched compact hematology analyzers that offer combined testing for Erythrocyte Sedimentation Rate (ESR) and complete blood count (CBC)/differential (Diff). HORIBA recently expanded its award-winning compact hematology instrument range with the launch of new models with ESR on board. At ADLM 2024, HORIBA is presenting the new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) which now offer combined testing for CBC/DIFF with ESR results from whole blood in 60 seconds.

Visitors to HORIBA’s booth at ADLM 2024 can learn more about the company’s innovative CoRA (Correlated Rouleaux Analysis) technology that has been used to integrate ESR into its three new analyzers. Combining CBC and 5-population white blood cell differential with rapid ESR, calibrated to the Westergren reference method, on one compact analyzer reduces costs per test and turnaround times, and saves laboratory space. Both the Yumizen H550E and H500E models have been further enhanced by offering new connectivity possibilities for data management through HORIBA’s Yumizen P8000 middleware, along with Yumicare. This remote technical support tool enables secure connection to the instrument to monitor workload, reagent consumption, quality control, and instrument alarms.

Also featuring is the new Yumizen C230 benchtop chemistry analyzer for small-volume laboratories with advanced and user-friendly features. This compact integrated solution is designed with system simplicity for efficient performance and processes tests with disposable cuvettes, enabling efficient resource usage. Paired with high-quality POINTE reagents, the new Yumizen C230 provides reliable test results. In addition, HORIBA is showcasing the new Yumizen C240 chemistry analyzer which is designed with system simplicity for expedient and efficient performance. Ideal for mid-sized to small labs, the Yumizen C240 is a compact and cost-efficient analyzer offering full walk-away capabilities and advanced features such as a washing station and pre-warmed detergent water.

Related Links:
HORIBA

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.